一、前言1969年潘寇朗宁(Pancuronium)问世,它在临床应用初期所呈现的某些优点曾使筒箭毒碱等传统肌松弛药逊色。随着深入的药理学研究和广泛的临床应用,发现该药可阻滞心脏 M-胆碱受体,引起心动过速与血压升高。药动学研究表明其在体内的存在时间较长,肝肾功能不全患者尤甚,连续用药有一 I. INTRODUCTION In 1969 Pancuronium was introduced and some of its advantages in the early stages of clinical use have undermined traditional muscle relaxants such as myostatin. With in-depth pharmacological studies and a wide range of clinical applications, found that the drug can block the heart M-choline receptors, causing tachycardia and blood pressure. Pharmacokinetic studies have shown that it exists in the body for a long time, especially in patients with liver and kidney dysfunction, continuous medication has a